A carregar...
The Current and Evolving Landscape of First‐Line Treatments for Advanced Renal Cell Carcinoma
Agents targeting the vascular endothelial growth factor (VEGF) and its receptors (VEGFRs), as well as the mammalian target of rapamycin (mTOR) and immune checkpoint receptor programmed death 1 (PD‐1) signaling pathway have improved clinical outcomes for patients with advanced renal cell carcinoma (R...
Na minha lista:
| Publicado no: | Oncologist |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley & Sons, Inc.
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6519762/ https://ncbi.nlm.nih.gov/pubmed/30158285 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2018-0267 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|